Bicyclic heteroaromatic compounds

Patent metadata

Field	Value
Publication number	US-9249140-B2
Application number	US-201214240584-A
Country	US
Kind code	B2
Filing date	Jul 26, 2012
Priority date	Aug 23, 2011
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1 , are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.

First claim

The invention claimed is:

1. A compound selected from the following compounds:

No.
Name

“A1”
N-Methyl-N-{3-[7-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-1H-

pyrrolo-[2,3-c]pyridin-2-yl]pyridin-2-yl}methanesulfonamide

“A2”
N-Methyl-N-{3-[7-(4-morpholin-4-ylphenylamino)-1H-

pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-yl}methanesulfonamide

“A3”
N-Methyl-N-{3-[7-(2-oxo-1,2,3,4-tetrahydroquinolin-6-

ylamino)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-yl}-

methanesulfonamide

“A4”
N-{3-[6-(2-Methoxy-4-morpholin-4-ylphenylamino)-7H-purin-8-

yl]pyridin-2-yl}-N-methylmethanesulfonamide

“A5”
N-Methyl-N-{3-[6-(4-morpholin-4-ylphenylamino)-7H-purin-8-

yl]-pyridin-2-yl}methanesulfonamide

“A6”
N-Methyl-N-{3-[6-(1-methyl-1H-pyrazol-4-ylamino)-7H-purin-

8-yl]pyridin-2-yl}methanesulfonamide

“A7”
N-Methyl-N-{3-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-ylamino)-

3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}methanesulfonamide

“A9”
N-(3-{[5-Cyano-2-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-4-

yl-amino]methyl}pyridin-2-yl)-N-methylmethanesulfonamide

“A10”
N-{3-[(3-Chloro-5-cyano-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-

methyl]pyridin-2-yl}-N-methylmethanesulfonamide

“A11”
N-{3-[(5-Cyano-2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-

methyl]pyridin-2-yl}-N-methylmethanesulfonamide

“A12”
N-{3-[(5-Cyano-1H-pyrrolo[2,3-b]pyridin-4-ylamino)methyl]-

pyridin-2-yl}-N-methylmethanesulfonamide

“A13”
N-Methyl-N-{3-[(5-methyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-

methyl]pyridin-2-yl}methanesulfonamide

“A14”
N-Methyl-N-{3-[(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-

methyl]-pyridin-2-yl}methanesulfonamide

“A15”
N-Methyl-N-{3-[(1H-pyrrolo[2,3-b]pyridin-4-ylamino)methyl]-

pyridin-2-yl}methanesulfonamide

“A16”
N-Methyl-N-{3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-

ylamino)-methyl]pyridin-2-yl}methanesulfonamide

“A17”
N-{3-[4-(2-Methoxy-4-morpholin-4-ylphenylamino)-3H-

imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-N-

methylmethanesulfonamide

“A18”
N-Methyl-N-{3-[6-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-7H-

purin-8-yl]pyridin-2-yl}methanesulfonamide

“A19”
N-{3-[(5-Cyano-2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-4-

ylamino)-methyl]pyridin-2-yl}-N-methylmethanesulfonamide

“A20”
N-(3-{[2-(4-Butylphenyl)-5-cyano-1H-pyrrolo[2,3-b]pyridin-4-

ylamino]methyl}pyridin-2-yl)-N-methylmethanesulfonamide

“A21”
N-(3-{[2-(4-Fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-b]-

pyridin-4-ylamino]methyl}pyridin-2-yl)-N-

methylmethanesulfonamide

“A22”
2-[[5-Cyano-2-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-4-

yl]amino]-N-methylbenzamide

“A23”
N-(3-{[5-Cyano-2-(2-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]-

pyridin-4-ylamino]methyl}pyridin-2-yl)-N-

methylmethanesulfonamide

“A24”
N-(3-{[2-(4-Fluorophenyl)-5-methyl-1H-pyrrolo[2,3-b]pyridin-4-

ylamino]methyl}pyridin-2-yl)-N-methylmethanesulfonamide

“A25”
N-(3-{[2-(4-Fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]-

methyl}pyridin-2-yl)-N-methylmethanesulfonamide

“A26”
(2,5-Difluorobenzyl)-[2-(4-fluorophenyl)-5-trifluoromethyl-1H-

pyrrolo-[2,3-b]pyridin-4-yl]amine

“A27”
N-{2-[2-(4-Fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-

b]pyridin-4-ylethynyl]phenyl}-N-methylmethanesulfonamide

“A28”
N-(2-{2-[2-(4-Fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3

-b]-pyridin-4-yl]ethyl}phenyl)-N-methylmethanesulfonamide

“A29”
N-(3-{[6-Bromo-2-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-7-

ylamino]methyl}pyridin-2-yl)-N-methylmethanesulfonamide

“A30”
2-[6-Bromo-2-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-7-

ylamino]-N-methylbenzamide

“A31”
N-(3-{[2-(4-Bromophenyl)-6-trifluoromethyl-3H-imidazo[4,5-

b]pyridin-7-ylamino]methyl}pyridin-2-yl)-N-

methylmethanesulfonamide

“A32”
2-[2-(4-Fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-

b]pyridin-4-ylamino]-N-methylbenzamide

“A33”
N-Methyl-2-[2-(6-morpholin-4-ylpyridin-3-yl)-5-trifluoromethyl-

Assignees

• Heinrich Timo
• Rohdich Felix
• Esdar Christina
• Krier Mireille
• Greiner Hartmut
• Merck Patent Gmbh

Inventors

• Heinrich Timo
• Rohdich Felix
• Esdar Christina
• Krier Mireille
• Greiner Hartmut

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P37/02

  Immunomodulators · CPC title